Revenue
2017
2018
2019
2020
2022
2023
2024
2025
FENNEC PHARMACEUTICALS INC. (FENC)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.6M | $47.5M | $23.8M | $1.8M | — | $170,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | $20.0M | $1.4M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $250,000 | $307,000 | $56,000 | $3.5M | $5.0M | $5.1M | $5.6M | $5.0M | $1.9M | $472,000 | $256,000 | $357,000 | $597,000 | $2.1M | $1.5M | $708,000 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating expenses | $50.9M | $45.0M | $34.0M | $24.0M | $17.2M | $18.1M | $13.0M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | −$6.3M | $2.6M | −$12.8M | −$22.6M | −$17.2M | −$17.9M | −$13.0M | −$10.4M | −$7.0M | −$2.9M | −$1.9M | −$2.9M | −$1.9M | −$3.6M | −$3.4M | −$4.6M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDAderived | — | — | — | — | — | — | — | — | — | — | — | — | −$1.9M | −$3.6M | −$3.4M | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net income | −$9.7M | −$436,000 | −$16.0M | −$23.7M | −$17.3M | −$18.1M | −$12.8M | −$9.9M | −$7.0M | −$2.8M | −$659,000 | −$2.2M | $1.8M | −$5.2M | $4.7M | −$7.8M | −$3.0M | −$13.6M | −$13.4M | −$16.4M | −$13.9M | −$6.9M | −$17.8M | −$3.7M | −$2.5M | −$1.6M | −$958,000 | −$398,000 | −$37,000 |
| Basic EPSper diluted share | -$0.34 | -$0.02 | -$0.60 | -$0.90 | -$0.67 | -$0.76 | -$0.64 | -$0.52 | -$0.47 | -$0.22 | -$0.06 | -$0.22 | $0.19 | -$0.21 | $0.20 | -$0.49 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$0.34 | -$0.02 | -$0.60 | -$0.90 | -$0.67 | -$0.76 | -$0.64 | -$0.52 | -$0.47 | -$0.22 | -$0.06 | -$0.22 | $0.17 | -$0.21 | $0.19 | -$0.49 | — | — | — | — | — | — | — | — | — | — | — | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 1, 2026Form 4 · 10b5-1 | Raykov RostyDirector | SellCommon shares | 9.7K | $9.62 | $93.8K | 130.1K |
| May 11, 2026Form 4 · 10b5-1 | RALLIS CHRIS ADirector | SellCommon Shares | 8.3K | $7.04 | $58.8K | 63.1K |
| May 1, 2026Form 4 · 10b5-1 | Raykov RostyDirector | SellCommon shares | 10.8K | $6.47 | $69.8K | 121.5K |
| Apr 1, 2026Form 4 · 10b5-1 | Raykov RostyDirector | SellCommon shares | 10.9K | $6.31 | $69.1K | 113.9K |
| Mar 2, 2026Form 4 · 10b5-1 | Raykov RostyDirector | SellCommon shares | 10.1K | $8.36 | $84.3K | 104.0K |